Differences

This shows you the differences between two versions of the page.

--- covid-19_vaccines:lipid_nanoparticle [2022/03/08 01:11]
liam [Relationship with the Canadian Government]
+++ covid-19_vaccines:lipid_nanoparticle [2022/11/24 19:45] (current)
liam [Intellectual Property and Patents]
@@ Line 13: / Line 13: @@
 ===== Intellectual Property and Patents =====
-The ownership and licensure of the LNP technology underlying the [[:mRNA]] [[:COVID-19 vaccines]] is controversial.
+The ownership and licensure of the LNP technology underlying the [[:mRNA]] [[:COVID-19 vaccines]] is controversial. See the below graphic from //Patent network analysis of mRNA-based vaccine candidates for COVID-19//:((Gaviria, M., & Kilic, B. (2021). //A network analysis of COVID-19 mRNA vaccine patents.// Nature Biotechnology, 39(5), 546–548. https://doi.org/10.1038/s41587-021-00912-9))
+{{:covid-19_vaccines:41587_2021_912_fig1_html_copy.jpg?600 |}}
 ==== Patents ====
@@ Line 20: / Line 22: @@
   * 2201121 - //Bilayer stabilizing components and their use in forming programmable fusogenic liposomes//((Madden, T. D., Cullis, P. R., & Holland, J. W. (1994). //Bilayer stabilizing components and their use in forming programmable fusogenic liposomes// (Canadian Intellectual Property Office Patent No. 2201121). https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2201121/summary.html?type=number_search&tabs1Index=tabs1_1))
 ==== Legal Challenges ====